Jounce Therapeutics JNCE

$ 1.88 0.0%

Annual report 2022
added 04-28-2023

Jounce Therapeutics Balance Sheet 2011-2024 | JNCE

Annual Balance Sheet Jounce Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-141 M	-81.8 M	-131 M	-33.5 M	-47.8 M	-23.5 M	-44.8 M	-45.2 M	-2.34 M	-	-	-
Long Term Debt	5.87 M	9.99 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	4.15 M	3.7 M	3.27 M	2.9 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	13.6 M	16.9 M	44.8 M	67 M	109 M	1.4 M	5.59 M	-	-	-
Total Current Liabilities	23.6 M	18.9 M	19.3 M	14.4 M	65.5 M	62.6 M	-	-	-	-	-	-
Total Liabilities	29.4 M	28.9 M	32.9 M	31.3 M	110 M	130 M	199 M	8.12 M	8.05 M	-	-	-
Deferred Revenue	-	-	1.93 M	-	55.2 M	51.1 M	80.5 M	-	-	-	-	-
Retained Earnings	-293 M	-242 M	-151 M	-107 M	-164 M	-89.6 M	-73.2 M	-59.5 M	-28 M	-	-	-
Total Assets	213 M	253 M	244 M	206 M	214 M	297 M	271 M	53 M	7.52 M	-	-	-
Cash and Cash Equivalents	151 M	95.5 M	147 M	53.2 M	47.9 M	23.6 M	44.8 M	-	-	-	-	-
Book Value	183 M	224 M	211 M	175 M	104 M	167 M	71.9 M	44.9 M	-535 K	-	-	-
Total Shareholders Equity	183 M	224 M	211 M	175 M	104 M	167 M	-69.1 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Jounce Therapeutics

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	6.93 M	-	9.01 M	9.99 M	10.9 M	11.9 M	12.8 M	13.6 M	13.6 M	13.6 M	13.6 M	16.9 M	16.9 M	16.9 M	16.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	28.7 M	-	25.7 M	28.9 M	29 M	27.7 M	25.7 M	32.9 M	32.9 M	32.9 M	32.9 M	31.3 M	31.3 M	31.3 M	31.3 M	110 M	110 M	110 M	110 M	130 M	130 M	130 M	130 M	199 M	199 M	199 M	199 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	392 K	1.93 M	1.93 M	1.93 M	1.93 M	-	-	64.9 M	62.9 M	55.2 M	55.2 M	55.2 M	59 M	51.1 M	52 M	69.2 M	76.7 M	80.5 M	80.5 M	80.5 M	80.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-344 M	-	-279 M	-242 M	-212 M	-182 M	-178 M	-151 M	-151 M	-151 M	-151 M	-107 M	-107 M	-107 M	-107 M	-164 M	-164 M	-164 M	-164 M	-89.6 M	-89.6 M	-89.6 M	-89.6 M	-73.2 M	-73.2 M	-73.2 M	-73.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	158 M	-	215 M	253 M	280 M	306 M	305 M	244 M	244 M	244 M	244 M	206 M	206 M	206 M	206 M	214 M	214 M	214 M	214 M	297 M	297 M	297 M	297 M	271 M	271 M	271 M	271 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	77.1 M	-	60.4 M	95.5 M	145 M	141 M	196 M	147 M	147 M	147 M	147 M	53.2 M	53.2 M	53.2 M	53.2 M	47.9 M	47.9 M	47.9 M	47.9 M	23.6 M	23.6 M	23.6 M	23.6 M	44.8 M	44.8 M	44.8 M	44.8 M	45.2 M	-	-	-	2.34 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	129 M	-	189 M	224 M	251 M	278 M	279 M	211 M	211 M	211 M	211 M	175 M	175 M	175 M	175 M	104 M	104 M	104 M	104 M	167 M	167 M	167 M	167 M	71.9 M	71.9 M	71.9 M	71.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	129 M	158 M	189 M	224 M	251 M	278 M	279 M	211 M	211 M	211 M	211 M	175 M	175 M	175 M	175 M	104 M	104 M	104 M	104 M	167 M	167 M	167 M	167 M	-69.1 M	-69.1 M	-69.1 M	-69.1 M	-58.8 M	-	-	-	-28 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency